Sanofi (SNY): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Sanofi ( SNY) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.1%. By the end of trading, Sanofi fell $0.51 (-1.0%) to $50.66 on light volume. Throughout the day, 1,267,912 shares of Sanofi exchanged hands as compared to its average daily volume of 2,101,200 shares. The stock ranged in price between $50.34-$50.81 after having opened the day at $50.76 as compared to the previous trading day's close of $51.17. Other companies within the Drugs industry that declined today were: StemCells ( STEM), down 12.5%, GTx ( GTXI), down 12.2%, Aoxing Pharmaceutical Company ( AXN), down 10.8% and PTC Therapeutics ( PTCT), down 9.1%.

Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $134.6 billion and is part of the health care sector. Shares are up 6.7% year to date as of the close of trading on Tuesday. Currently there are 4 analysts that rate Sanofi a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, GW Pharmaceuticals PLC ADR ( GWPH), up 96.9%, Delcath Systems ( DCTH), up 91.4%, DARA Biosciences ( DARA), up 41.2% and Genvec ( GNVC), up 27.7% , were all gainers within the drugs industry with Sarepta Therapeutics ( SRPT) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)